Literature DB >> 10821810

Intracoronary beta-irradiation with a liquid (188)re-filled balloon: six-month results from a clinical safety and feasibility study.

M Höher1, J Wöhrle, M Wohlfrom, H Hanke, R Voisard, H H Osterhues, M Kochs, S N Reske, V Hombach, J Kotzerke.   

Abstract

BACKGROUND: Coronary irradiation is a new concept to reduce restenosis. We evaluated the feasibility and safety of intracoronary irradiation with a balloon catheter filled with (188)Re, a liquid, high-energy beta-emitter. METHODS AND
RESULTS: Irradiation with 15 Gy at 0.5-mm tissue depth was performed in 28 lesions after balloon dilation (n=9) or stenting (n=19). Lesions included 19 de novo stenoses, 4 occlusions, and 5 restenoses. Irradiation time was 515+/-199 seconds in 1 to 4 fractions. There were no procedural complications. One patient died of noncardiac causes at day 23. One asymptomatic patient refused 6-month angiography. Quantitative angiography after intervention showed a reference diameter of 2. 77+/-0.35 mm and a minimal lumen diameter of 2.36+/-0.43 mm. At 6-month follow-up, minimal lumen diameter was 1.45+/-0.88 mm (late loss index 0.57). Target lesion restenosis rate (>50% in diameter) was low (12%; 3 of 26). In addition, we observed 9 stenoses at the proximal or distal end of the irradiation zone, potentially caused by the short irradiation segment and the decreasing irradiation dose at its borders ("edge" stenoses). The total restenosis rate was 46% and was significantly lower (29% vs 70%, P=0.042) when the length of the irradiated segment was more than twice the lesion length.
CONCLUSIONS: Coronary irradiation with a (188)Re-filled balloon is technically feasible and safe, requiring only standard percutaneous transluminal coronary angioplasty techniques. The target lesion restenosis rate was low. The observed edge stenoses appear to be avoidable by increasing the length of the irradiated segment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821810     DOI: 10.1161/01.cir.101.20.2355

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Intracoronary beta-brachytherapy using a rhenium-188 filled balloon catheter in restenotic lesions of native coronary arteries and venous bypass grafts.

Authors:  Jochen Wöhrle; Bernd Joachim Krause; Thorsten Nusser; Felix M Mottaghy; Thomas Habig; Matthias Kochs; Jörg Kotzerke; Sven N Reske; Vinzenz Hombach; Martin Höher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-22       Impact factor: 9.236

2.  Intracoronary radiation therapy: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2001-12-01

3.  Endovascular gamma irradiation for the prevention restenosis after angioplasty of femoropopliteal de novo stenoses.

Authors:  Karsten Krueger; Mark Bendel; Markus Zaehringer; David Strohe; Christopher Bangard; Carsten Weise; Rolf-Peter Mueller; Klaus Lackner
Journal:  Eur Radiol       Date:  2005-08-23       Impact factor: 5.315

Review 4.  Prevention of restenosis with intravascular beta-radiotherapy.

Authors:  G L Kaluza; P T Zymek; A E Raizner
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

5.  Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.

Authors:  Ekaterina Dadachova; Antonio Nakouzi; Ruth A Bryan; Arturo Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

6.  Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.

Authors:  Ekaterina Dadachova; Joshua D Nosanchuk; Li Shi; Andrew D Schweitzer; Annie Frenkel; Jerome S Nosanchuk; Arturo Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-05       Impact factor: 11.205

7.  Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Authors:  Ekaterina Dadachova; Mahesh C Patel; Sima Toussi; Christos Apostolidis; Alfred Morgenstern; Martin W Brechbiel; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall; Harris Goldstein
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.